Multicenter Trial Investigating Performance and Safety of the Medical Device SiPore21®

Prior treatment

• History (self-reported) of myocardial infarction or stroke 6 months prior to V1
• History (\<3 years prior to V1) or presence (self-reported) of:
  • exocrine pancreatic insufficiency, chronic pancreatitis
  • chronic inflammatory bowel disease, celiac disease
  • diverticulosis (usually affecting the large intestine), adhesions, chronic constipation
• State after pancreatic head resection with the need for additional intake of pancreatic enzymes (self-reported)
• Major surgery of esophagus, stomach, intestine including colon which took place \<3 years prior to V1, or \>3 years prior to V1 in case of related current clinical symptoms (self-reported)
• Blood donation/other major blood loss or blood transfusion, that may interfere with the study as per investigator's judgment, within 56 days prior to V1 and any blood donation or transfusion during the study
• Current treatment/supplementation for weight management (e.g., fat binder/burner, carb blocker, satiety products) or known to influence weight (e.g., systemic corticosteroids)
• Extreme diet form (e.g., ketogenic, very low carbohydrate) during the last 3 months prior to study
• Participation in another study during the last 30 days prior to V1

Other illness

• Known allergy or hypersensitivity to the components of the IMD or placebo (self-reported)
• Type 1 diabetes (T1D)/Latent Autoimmune Diabetes in Adult or secondary diabetes (self-reported)
• Uncontrolled hypertension (regularly \>179/109 mmHg \[self-reported\] and as per investigator's judgement based on screening procedures at V1)
• Medical conditions that require medications taken during meals
• History of or current abuse of drugs, alcohol or medication
• Any severe diseases/disorder (e.g., chronic kidney disease, neoplastic disease or psychiatric disorder) which may interfere with the compliance to the study procedures as per investigator's judgement
• Belonging to a vulnerable population, having any condition or other reason which in the opinion of the investigator would confound the conduct of the study or interpretation of the study results

Lab values

• Clinically significant deviation, based on investigators judgment, in blood laboratory values at V1 of blood status (hemoglobin, erythrocytes, platelets, leucocytes, reticulocytes), kidney parameters (creatinine, cystatin C and estimated glomerular filtration rate), thyroid hormone status: thyroid-stimulating hormone (TSH)
• Deviation in blood laboratory values at V1 of liver parameters (aspartate aminotransferase \[ASAT\], alanine transaminase \[ALAT\], alkaline phosphatase and γ-glutamyl transpeptidase \[Gamma-GT\]) that is clinically significant based on investigators judgment
• Previous or current metformin or other medical anti-diabetic treatment or blood glucose levels reducing/influencing treatment/supplementation within 30 days prior to V1 and during the study

Other

• Clinically relevant abnormal electrocardiogram (ECG) at V1
• Self-reported regular average consumption of \>1 L/day total of sugary beverages (e.g., soft drinks, fruit juices, energy drinks) and/or \>200 g/day total of food based on simple sugar(s) between meals (e.g., commercial candies, dried fruit)
• Pregnancy, lactation or active planning to achieve pregnancy
• Relative of the investigator or an employee at the clinical study site and Sponsor

• Male or female 18-70 years old
• HbA1c level ≥42 to 58 mmol/mol (≥6 to 7.5% - according to Diabetes Control and Complications Trial \[DCCT, 1987\]) at V1 For Poland only: HbA1c level ≥42 to 53 mmol/mol (≥6 to 7% - according to the Official Journal of the Diabetes Poland, 2023 Vol. 3 Issue 1) at V1
• Body mass index (BMI) \>25 kg/m2 and 40 kg/m2
• Regular intake of 3 main meals (self-reported)
• Readiness and ability to:
  • use the study treatment as recommended and attend all scheduled visits
  • comply with all further study procedures
• Readiness to maintain the current diet and level of physical activity during the study
• Readiness not to participate in another clinical study during this study
• Women of childbearing potential: commitment to use medically recognized contraception methods during the treatment period
• Written informed consent by the participant following written and oral information by the investigator regarding nature, purpose, consequences and possible risks of the clinical study